ketoconazole and darexaban

ketoconazole has been researched along with darexaban in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Eltink, C; Garcia-Hernandez, A; Groenendaal, D; Heeringa, M; Kadokura, T; Mol, R; Onkels, H; Strabach, G	1

Trials

1 trial(s) available for ketoconazole and darexaban

Article	Year
The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein. Clinical pharmacology in drug development, 2014, Volume: 3, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Azepines; Benzamides; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Factor Xa Inhibitors; France; Glucuronides; Half-Life; Healthy Volunteers; Humans; Ketoconazole; Male; Metabolic Clearance Rate; Middle Aged; Young Adult	2014

Article

Year

The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.

Clinical pharmacology in drug development, 2014, Volume: 3, Issue:3

Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Azepines; Benzamides; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Factor Xa Inhibitors; France; Glucuronides; Half-Life; Healthy Volunteers; Humans; Ketoconazole; Male; Metabolic Clearance Rate; Middle Aged; Young Adult

2014